Embedded Files
Summary
Summary
New reports identify a gene mutation that may protect against Alzheimer's disease. The study, published in the journal Nature Medicine, was conducted by researchers from the University of California, San Francisco (UCSF) and the University of Texas Southwestern Medical Center (UTSW).
The researchers analyzed the genomes of over 10,000 people with Alzheimer's disease and over 10,000 healthy controls. They found that a rare mutation in a gene called APOB, which encodes a protein that transports cholesterol and other fats in the blood, was associated with a lower risk of developing Alzheimer's disease. The mutation, called A673T, reduces the levels of APOB protein and lowers the risk of cardiovascular disease as well.
They also performed experiments in mice and human cells to understand how the APOB mutation affects the brain. They found that the mutation reduces the production and accumulation of amyloid-beta, a toxic protein that forms plaques in the brains of people with Alzheimer's disease. The mutation also enhances the clearance of amyloid-beta by increasing the activity of an enzyme called ABCA1, which transports cholesterol and other fats out of the brain cells.
Research suggests that the APOB mutation may offer a new target for developing drugs or gene therapies for preventing or treating Alzheimer's disease. They also hope that their findings will inspire more research on the role of cholesterol and other fats in brain health and disease.
How APOB Could Protect Against Alzheimers
How APOB Could Protect Against Alzheimers
APOB is a gene that encodes for apolipoprotein B (ApoB), a protein that is integral in the metabolism of lipids, or fats, in the body. It is a component of low-density lipoprotein (LDL), often referred to as 'bad cholesterol'. High levels of LDL cholesterol are associated with an increased risk of cardiovascular diseases.
Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of amyloid-beta plaques and tau tangles in the brain. The A673T mutation is a rare genetic variation that results in reduced levels of ApoB protein and is associated with a lower risk of both cardiovascular disease and Alzheimer's disease.
The exact mechanisms by which this mutation reduces the risk of Alzheimer's are not completely understood, but several theories have been proposed:
Amyloid-beta Clearance: As mentioned previously, ApoB may be involved in the transport of amyloid-beta, a protein that accumulates in the brains of Alzheimer's patients. Lower levels of ApoB could potentially lead to a reduced transportation and accumulation of amyloid-beta in the brain.
Inflammation: High levels of LDL cholesterol are associated with inflammation, which is a known risk factor for Alzheimer's disease. Lower levels of ApoB, and subsequently LDL cholesterol, could reduce inflammation and therefore the risk of Alzheimer's disease.
Vascular Health: There is a known association between cardiovascular health and cognitive function. Good vascular health is associated with a reduced risk of cognitive decline and dementia. By reducing the risk of cardiovascular disease, the A673T mutation could indirectly reduce the risk of Alzheimer's disease.
Toxin Hypothesis: Fats can store toxins, and the movement of these fats could potentially lead to the filtration or elimination of these toxins. However, there is limited evidence to support the theory that the reduction in Alzheimer's risk is directly related to toxin filtration.
In conclusion, while there are several theories about the relationship between ApoB and Alzheimer's disease, the exact mechanisms are not yet fully understood. Further research is needed to clarify the role of ApoB and cholesterol metabolism in the development of Alzheimer's disease.
Page updated
Google Sites
Report abuse